Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GLP-1 drugs like Ozempic have been linked to a rare eye condition called NAION, but experts say the overall risk is "very, very low" and doesn't justify stopping the medication. Patients should stay alert to sudden vision changes and consult an eye care provider promptly if they occur.
GLP-1 receptor agonists — the blockbuster class of drugs behind Ozempic and Wegovy — have been making headlines for more than just weight loss. Studies now suggest a possible link between these medications and nonarteritic anterior ischemic neuropathy (NAION), a form of vision loss caused by reduced blood flow to the optic nerve. But experts are urging calm over alarm.
Speaking at Academy 2026, optometry professor Dr. Leonard Messner stressed that the absolute risk remains "very, very low" and that current evidence does not support discontinuing GLP-1s over NAION concerns. He noted that one large population-based study of over 37 million patients found only a "modest increase" in risk — one not much higher than the baseline risk tied to type 2 diabetes itself. A smaller, single-center study did find a four- to sevenfold higher risk, but Messner attributed that partly to its focus on high-risk patients at a tertiary care center.
Key Takeaways:
Why it matters: With millions of patients on GLP-1s globally — and lawsuits already filed against Novo Nordisk and Eli Lilly — clinicians need clear, evidence-based guidance. The message: vigilance, not panic.
